Barclays Increases BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target to $11.00

BioCryst Pharmaceuticals (NASDAQ:BCRX) had its target price hoisted by Barclays from $8.00 to $11.00 in a research report report published on Wednesday morning,Benzinga reports. Barclays currently has an equal weight rating on the biotechnology company’s stock.

Several other research analysts have also recently issued reports on the stock. StockNews.com raised shares of BioCryst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Tuesday. JPMorgan Chase & Co. boosted their price objective on shares of BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the stock an “overweight” rating in a report on Tuesday. Evercore ISI increased their target price on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a research note on Monday, January 13th. HC Wainwright restated a “buy” rating and issued a $30.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $18.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Friday, January 31st. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $16.56.

BioCryst Pharmaceuticals Stock Up 0.6 %

BCRX stock opened at $9.98 on Wednesday. The business has a 50 day moving average of $7.87 and a 200 day moving average of $7.89. The firm has a market cap of $2.09 billion, a PE ratio of -16.36 and a beta of 1.08. BioCryst Pharmaceuticals has a twelve month low of $5.23 and a twelve month high of $11.11.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The firm had revenue of $131.50 million during the quarter, compared to analysts’ expectations of $126.64 million. BioCryst Pharmaceuticals’s quarterly revenue was up 40.8% on a year-over-year basis. During the same period in the previous year, the firm earned $0.28 EPS. On average, research analysts expect that BioCryst Pharmaceuticals will post -0.36 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Headlands Technologies LLC purchased a new stake in BioCryst Pharmaceuticals in the first quarter worth about $32,000. GF Fund Management CO. LTD. bought a new position in shares of BioCryst Pharmaceuticals during the 4th quarter valued at approximately $33,000. GAMMA Investing LLC increased its holdings in BioCryst Pharmaceuticals by 1,161.8% in the 1st quarter. GAMMA Investing LLC now owns 5,918 shares of the biotechnology company’s stock worth $44,000 after acquiring an additional 5,449 shares in the last quarter. Venturi Wealth Management LLC bought a new stake in BioCryst Pharmaceuticals during the 4th quarter worth approximately $46,000. Finally, R Squared Ltd purchased a new position in BioCryst Pharmaceuticals during the fourth quarter valued at approximately $48,000. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.